These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 34452358)
1. Nonhuman Adenoviral Vector-Based Platforms and Their Utility in Designing Next Generation of Vaccines for Infectious Diseases. Alhashimi M; Elkashif A; Sayedahmed EE; Mittal SK Viruses; 2021 Jul; 13(8):. PubMed ID: 34452358 [TBL] [Abstract][Full Text] [Related]
2. Adenoviral vector immunity: its implications and circumvention strategies. Ahi YS; Bangari DS; Mittal SK Curr Gene Ther; 2011 Aug; 11(4):307-20. PubMed ID: 21453277 [TBL] [Abstract][Full Text] [Related]
3. Development of nonhuman adenoviruses as vaccine vectors. Bangari DS; Mittal SK Vaccine; 2006 Feb; 24(7):849-62. PubMed ID: 16297508 [TBL] [Abstract][Full Text] [Related]
4. Adenovirus vector-based vaccine for infectious diseases. Sakurai F; Tachibana M; Mizuguchi H Drug Metab Pharmacokinet; 2022 Feb; 42():100432. PubMed ID: 34974335 [TBL] [Abstract][Full Text] [Related]
5. Current strategies and future directions for eluding adenoviral vector immunity. Bangari DS; Mittal SK Curr Gene Ther; 2006 Apr; 6(2):215-26. PubMed ID: 16611043 [TBL] [Abstract][Full Text] [Related]
6. Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines. Coughlan L Front Immunol; 2020; 11():909. PubMed ID: 32508823 [TBL] [Abstract][Full Text] [Related]
8. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Mack CA; Song WR; Carpenter H; Wickham TJ; Kovesdi I; Harvey BG; Magovern CJ; Isom OW; Rosengart T; Falck-Pedersen E; Hackett NR; Crystal RG; Mastrangeli A Hum Gene Ther; 1997 Jan; 8(1):99-109. PubMed ID: 8989999 [TBL] [Abstract][Full Text] [Related]
9. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Hartman ZC; Appledorn DM; Amalfitano A Virus Res; 2008 Mar; 132(1-2):1-14. PubMed ID: 18036698 [TBL] [Abstract][Full Text] [Related]
10. Significance of Preexisting Vector Immunity and Activation of Innate Responses for Adenoviral Vector-Based Therapy. Wang WC; Sayedahmed EE; Mittal SK Viruses; 2022 Dec; 14(12):. PubMed ID: 36560730 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of innate immunity and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse model. Sharma A; Bangari DS; Tandon M; Hogenesch H; Mittal SK Virus Res; 2010 Oct; 153(1):134-42. PubMed ID: 20659505 [TBL] [Abstract][Full Text] [Related]
12. Distinct patterns of whole blood transcriptional responses are induced in mice following immunisation with adenoviral and poxviral vector vaccines encoding the same antigen. Sheerin D; Dold C; O'Connor D; Pollard AJ; Rollier CS BMC Genomics; 2021 Oct; 22(1):777. PubMed ID: 34717548 [TBL] [Abstract][Full Text] [Related]